Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252313091 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Dominique Bollino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Institute, West Virginia University, Morgantown, WV 26506, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Proto-Oncogene Proteins c-bcl-2, Myeloid Cell Leukemia Sequence 1 Protein, Xenograft Model Antitumor Assays. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Servier Pharmacueticals, Servier Pharmaceuticals.
Abstract (Originalsprache)
Our previous studies have demonstrated that pegcrisantaspase (PegC), a long-acting Erwinia asparaginase, synergizes with the BCL-2 inhibitor Venetoclax (Ven) in vitro and in vivo; however, the anti-leukemic activity of E. coli-derived asparaginases in combination with BCL-2 inhibition, and potential synergy with inhibitors of MCL-1, a key resistance factor of BCL-2 inhibition, has yet to be determined. Using a combination of human AML cells lines, primary samples, and in vivo xenograft mouse models, we established the anti-leukemic activity of the BCL-2 inhibitor S55746 and the MCL-1 inhibitor S63845, alone and in combination with the long-acting E. coli asparaginase calaspargase pegol-mknl (CalPegA). We report that CalPegA enhances the anti-leukemic effect of S55746 but does not impact the activity of S63845. The S55746-CalPegA combination inhibited protein synthesis and increased eIF4E/4EBP1 interaction, suggesting an inhibition of translational complex formation. These results support the clinical evaluation of CalPegA in combination with BCL-2 inhibition for AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Cancer Institute, West Virginia University, Morgantown, WV 26506, USA.
- Department of Medical Oncology, School of Medicine, West Virginia University, Morgantown, WV 26506, USA.
- The Biology Department, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.
- Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
ORCID-Profile: Ashkan Emadi
Förderung
- Servier Pharmacueticals
- Servier Pharmaceuticals
Zitieren
APA
Bollino, D., Ma, X., Tighe, K. M., Casildo, A., Richard, K., Passaniti, A., Carter-Cooper, B., Strovel, E. T., & Emadi, A. (2024). Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252313091
Vancouver
Bollino D, Ma X, Tighe KM, Casildo A, Richard K, Passaniti A, et al. Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252313091
BibTeX
@article{Bollino2024,
author = {Bollino, Dominique and Ma, Xinrong and Tighe, Kayla M and Casildo, Andrea and Richard, Katharina and Passaniti, Antonino and Carter-Cooper, Brandon and Strovel, Erin T and Emadi, Ashkan},
title = {Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252313091}
}
EUVIMED